B, consensus $10.44B. Discover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving Strong ...

Deerfield Management claims that Alcon Research is seeking a discounted takeover of Aurion Biotech while blocking the startup ...

As Alcon Research seeks to block investee Aurion Biotech from listing on the New York Stock Exchange, another investor has ...

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare ...

Reports Q4 revenue $2.48B, consensus $2.47B. “In 2024, our unwavering focus on innovation and operational excellence delivered another set of ...

SYSTANE PRO PF is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all ...

An unusual legal battle over a biotech startup's IPO plans escalated to another level on Valentine's Day, according to two ...

Alcon announced the US launch of SYSTANE PRO Preservative-Free (PF) as part of the company’s dry eye products. The ...

The first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society ...

Traditional SLT involves using a laser to manipulate the eye's trabecular meshwork, located around the base of the cornea, ...

Full-year 2024 sales of $9.8 billion, up 5%, or up 6% constant currency1 (cc) Full-year 2024 diluted EPS of $2.05, up 5% on a reported basis, or up 11% cc; core diluted EPS2 of $3.05 up 11% ...

Aurion Biotech Inc.’s public offering has been delayed after the company missed a filing deadline with the SEC, its attorney ...